Maravai LifeSciences (NASDAQ:MRVI) Sets New 1-Year High – What’s Next?

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) hit a new 52-week high on Tuesday . The company traded as high as $8.87 and last traded at $8.7450, with a volume of 1027230 shares traded. The stock had previously closed at $8.43.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $6.00 price target on shares of Maravai LifeSciences in a report on Friday, May 8th. Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.25.

Maravai LifeSciences Trading Down 1.1%

The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. The company has a market cap of $2.31 billion, a P/E ratio of -17.12 and a beta of 0.63. The stock has a 50-day moving average of $6.50 and a two-hundred day moving average of $4.70.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%.The business had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. On average, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the transaction, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. The trade was a 6.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Maravai LifeSciences by 2.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after buying an additional 178,445 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Maravai LifeSciences by 1.7% in the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock worth $20,148,000 after acquiring an additional 104,355 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Maravai LifeSciences by 0.9% in the 1st quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock worth $12,069,000 after acquiring an additional 39,600 shares during the last quarter. Tejara Capital Ltd lifted its position in Maravai LifeSciences by 23.1% in the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after acquiring an additional 566,768 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Maravai LifeSciences by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock valued at $9,259,000 after acquiring an additional 34,447 shares in the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.